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Available online 26 October 2011Background: Beta blocker therapy may induce depressive symptoms, although current evidence
is conflicting. We examined the association between beta blocker therapy and depressive symp-
toms in percutaneous coronary intervention (PCI) patients and the extent to which there is a
dose–response relationship between beta blocker dose and depressive symptoms.
Methods: Patients treated with PCI (N=685) completed the depression scale of the Hospital
Anxiety and Depression Scale 1 and 12months post PCI. Information about type and dose of
beta blocker use was extracted from medical records.
Results: Of all patients, 68% (466/685)were on beta blocker therapy at baseline. In adjusted analysis,
beta blocker use at 1 month post PCI (OR: 0.82; 95% CI: 0.53–1.26) was not significantly associated
with depressive symptoms. At 12 months post PCI, therewas a significant relationship betweenbeta
blocker use and depressive symptoms (OR: 0.51; 95% CI: 0.31–0.84), with beta blocker therapy as-
sociatedwith a 49% risk reduction in depressive symptoms. Therewas a dose–response relationship
between beta blocker dose and depressive symptoms 12 months post PCI, with the risk reduction in
depressive symptoms in relation to a lowdose being 36% (OR: 0.64; 95%CI: 0.37–1.10) and 58% (OR:
0.42; 95% CI: 0.24–0.76) in relation to a high dose.
Conclusions: Patients treated with beta blocker therapy were less likely to experience depressive
symptoms 12 months post PCI, with there being a dose–response relationship with a higher dose
providing a more pronounced protective effect.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
Beta blocker
Depressive symptoms
Dose1. Introduction
Beta blocker therapy has clear survival benefits in patients
with chronic heart failure (Javed and Deedwania, 2009), in pa-
tients following a myocardial infarction (MI), and in patientsy artery disease;CNS,
Depression Scale;MI,
cutaneous coronary
epartment of Cardiolo-
Netherlands. Tel.: +31
).
ier OA license.with hypertropic obstructive cardiomyopathy (Bangalore et al.,
2007). Beta blockers are also used in the treatment of supraven-
tricular arrhythmias, to control ventricular arrhythmias related
to sympathetic activation, and to prevent postoperative cardiac
complications during noncardiac surgery (Bangalore et al.,
2007). Beta blockers are prescribed not only for cardiovascular
disease but also formigraine prophylaxis, various anxiety disor-
ders, tremor, and aggressive disorders secondary to organic
brain illnesses (Elliott, 1977; Jankovic and Fahn, 1980).
There has been a long-standing concern, however, that beta
blocker use might be associated with neuropsychological side
effects, such as depression. In 1967 Waal already reported a
50% incidence of depression in patients prescribed more than
120 mg/day of propranolol for hypertension, although this
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Experts have suggested that the inhibitory actions of beta
blockers on the beta receptors and serotonin receptors in the
central nervous systemmay be involved in the pathophysiology
of depressive disorders (1977). However, subsequent publica-
tions have reported conflicting results (Avorn et al., 1986; Bright
and Everitt, 1992; Ko et al., 2002; Krantz et al., 1982; Patten and
Love, 1993; Schleifer et al., 1991; Thiessen et al., 1990). These
conflicting results may in part be attributed to differences in
study design and case definition, and in part to confounding dis-
ease states (Ried et al., 1998). Amore recent andwell conducted
study that used a prospective design showedno relationship be-
tween beta blocker use and depression — neither depressive
symptoms nor depressive disorder (vanMelle et al., 2006). A re-
view by Verbeek et al. did not ruled out that specific types of
beta blockers might have a depressogenic effect but this weak
evidence should not be decisive to prescribe beta blockers to pa-
tients (Verbeek et al., 2011).
Given that depression is associatedwith a 2-fold risk ofmor-
tality in patients with coronary artery disease (CAD) (Nicholson
et al., 2006), and even minimal symptoms of depression have
been shown to predict short-term prognosis in patients treated
with percutaneous coronary intervention (PCI) with drug elut-
ing stenting (Pedersen et al., 2009), it is important to know
whether beta blocker therapy is linked to depression.
We examined the association between beta blocker ther-
apy and depressive symptoms in patients treated with PCI
and the extent to which there is a dose–response relationship
between beta blocker dose and depressive symptoms.
2. Methods
2.1. Patient population and design
The study population (N=685) consisted of two cohorts,
all were treated with the Taxus stent. Patients were enrolled
in the study if they were at least 18 years of age, had stable or
unstable angina or provokable ischemia, and were undergoing
PCI for a single, previously untreated lesion in a native coronary
artery (Stone et al., 2004). The exclusion criteria were PCI for a
lesion involving a previously implanted stent or patients re-
ceiving only BMS in the DES era (Stone et al., 2004). Depressive
symptoms were assessed within 1 month post PCI (referred to
as baseline in the remainder of the article) and 12 months post
PCI in both cohorts.
The first consecutive cohort (cohort I) was comprised of
406 patients treated with PCI between July 1, 2003 and July 1,
2004. These patients completed the Hospital Anxiety and De-
pression Scale (HADS) at baseline and 12 months post PCI.
Only patients who completed the HADS at baseline as well as
12 months post PCI were included in this study. Differences
on baseline characteristics between responders and excluded/
non-responders were found on age and diabetes. Excluded
and non-responders were more likely to be older (mean
age=64±10 vs. 62±11) but less likely to have diabetes
(15% versus 19%). No other systematic differences were found
on baseline characteristics, including cardiac medication.
The second consecutive cohort (cohort II) included 279
patients treated with PCI between January 2006 and August
2006, who completed the HADS at baseline and 12 months
post PCI. Only patients who completed the HADS at baselineas well as 12 months post PCI were included in this study.
Differences on baseline characteristics between responders
and excluded/non-responders were found on age and prior
PCI. Excluded and non-responders were more likely to be
younger (mean age=61±11 vs. 63±11) but less likely to
have undergone a prior PCI (23% versus 28%). No other sys-
tematic differences were found on baseline characteristics,
including cardiac medication.
Differences between Cohorts I and II were the following.
Patients enrolled in cohort I were more likely to have hyper-
cholesterolemia, a prior MI, a PCI indication for stable AP, and
they were more likely on a beta blocker, calcium antagonist,
ACE inhibitor and diuretics. Furthermore, there were fewer
smokers in Cohort I.2.2. Demographic and clinical variables
Information on demographic and clinical variables was
obtained from the patients' medical records or from purpose-
designed questions in the questionnaire. Demographic variables
included age and gender. Clinical variables included cardiac his-
tory (i.e., previousMI, PCI or coronary artery bypass graft surgery
(CABG)), indication for PCI (MI, stable or unstable angina), stent
type (sirolimus eluting stent or paclitaxel-eluting stent) smoking
status, hypertension, hypercholesterolemia, diabetes, familiar
cardiac history and multivessel disease. Cardiac medication in-
cluded aspirin, beta blockers, calcium antagonists, nitrates, ACE
inhibitors, and statins. Information on all the clinical variables
was collected during and immediately after the procedure.
Given the objective of the study, we collected detailed infor-
mation on both the type of beta blocker used and the dose. Types
of beta blockers prescribed included bisoprolol, metoprolol,
atenolol, carvedilol, nebivolol, propranolol, labetolol, pindolol,
sotalol, and celiprolol. Dose of beta blocker therapy was divided
into low versus high, with a low dose defined as patients using
less than 25% of the maximum recommended therapeutic
dose, whereas a high dose was defined as exceeding or equal
to 25% of the maximum recommended therapeutic dose (van
Gestel et al., 2008). For bisoprolol, a maximum recommended
therapeutic dose of 20 mg was used, for metoprolol 400 mg,
for atenolol 100 mg, for carvedilol 50 mg, for nebivolol 10 mg,
for propranolol 320 mg, for labetolol 800 mg, for pindolol
30 mg, for sotalol 320 mg, and for celiprolol 400 mg.2.3. Depressive symptoms
Depressive symptoms were assessed with the 7-item de-
pression subscale of the Hospital Anxiety and Depression
Scale (HADS) (Bjelland et al., 2002). All items are answered
on a four-point Likert scale from 0 to 3 with a score range of
0–21, with a higher score indicating more depressive symp-
tomatology. Depressive symptoms were dichotomized using
the standardized cut-off≥8. The HADS is a valid and internally
consistent measure, as indicated by Cronbach's α=0.68–0.93
for anxiety and Cronbach's α=0.67–0.90 for depressive symp-
toms (Bjelland et al., 2002). An advantage of usingHADS in car-
diac patients is that the scale contains no somatic items,
decreasing the likelihood that scores are confounded by disease
severity (Herrmann-Lingen et al., 2001).
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Prior to statistical analyses, Cohorts I and II were pooled as
depressive symptoms were measured with the HADS in both
cohorts. Discrete variables were compared with the χ2 test
(Fisher's exact test when appropriate) and continuous variables
with the Student's t-test for independent samples. Univariable
and multivariable logistic regression analyses were performed
to evaluate the influence of beta blocker use on depressive
symptoms at baseline and at 12 months post PCI. In multivari-
able logistic analysis, we adjusted for age, gender, prior MI,
prior PCI, prior CABG, current smoking, hypertension, hypercho-
lesterolemia, diabetes, multivessel disease, indication for PCI,
and family history. The results of the regression analyses are
presented as odds ratios (OR) with the corresponding 95% con-
fidence intervals (CI). All statistical analyses were performed
with SPSS for Windows version 15.0.
3. Results
3.1. Patient baseline characteristics stratiﬁed by beta
blocker therapy
Of all patients, 68% (466/685) of patients were prescribed
beta blocker therapy. Baseline characteristics for the total
sample and stratified by beta blocker therapy are displayed
in Table 1. Patients who were on beta blocker therapy were
more likely to be younger (62 vs 65 years, p=0.02), to
have a prior MI (39 vs 30, p=0.02), to have a PCI indication
for unstable angina pectoris (40 vs 31, p=0.02) and to be
prescribed aspirin (66% vs 40%, pb0.001), calcium antago-
nists (36% vs 26%, p=0.05), ACE inhibitors (20 vs 17,Table 1
Patient baseline characteristics (merged Cohorts I and II) stratified by beta blocker
Total
(n=685)
Be
(n
Demographic characteristics
Age, years (SD) 63 (11) 62
Male (%) 76 35
Cardiac history
Prior MI 36 39
Prior CABG 11 11
Prior PCI 25 25
Risk factors
Current smoking 17 17
Hypertension 48 49
Diabetes 19 18
Family history 48 47
Multivessel disease 56 56
PCI indication
Stable angina pectoris 49 48
Unstable angina pectoris 37 40
Acute MI 14 12
Cardiac medication
Aspirin 58 66
Calcium antagonist 33 36
Nitrates 19 20
ACE inhibitors 38 41
Statins 89 91
Diuretics 8 12
•Results are presented as % unless otherwise indicated.
•MI = myocardial infarction; CABG = coronary artery bypass grafting; and PCI = pp=0.02) and statins (91 vs 85, p=0.01) but were less likely
to have a PCI indication for acute MI (12 vs 18, p=0.02) and
stable angina pectoris (48 vs 52, p=0.02) as compared with
patients who were not on beta blocker therapy.3.2. Prevalence of depressive symptoms
The prevalence of depression (cut-off of ≥8 on the HADS
depression scale) in Cohort I was 19.7% at baseline and 12.1%
at 12 months post PCI, and in Cohort II 12.2% at baseline and
11.8% at 12 months post PCI.3.3. Depressive symptoms and beta blocker use at baseline and
at 12 months
At baseline, beta blocker use was not associated with de-
pressive symptoms (OR: 0.85; CI: 0.55–1.29) in unadjusted
analysis, while at 12 months post PCI, there was a statistically
significant association between beta blocker use and depres-
sive symptoms (OR: 0.53; CI: 0.33–0.84). The association be-
tween beta blocker use and depressive symptoms (OR: 0.51;
CI: 0.31–0.84) 12 months post PCI remained after adjustment
for potential demographic and clinical confounders, with pa-
tients on beta blocker therapy having a 49% risk reduction in
depressive symptoms (Table 2). When we add baseline HADS
in the multivariable model the odds ratio is even more signifi-
cant at 12 months post PCI namely OR: 0.46 (CI: 0.25–0.83).
When we only adjust for baseline HADS and the use of
beta blocker therapy the outcome is comparable namely
OR: 0.46 (CI: 0.26–0.82).therapy⁎.
ta blocker
=466)
No beta blocker
(n=219)
p-value
(10) 65 (11) 0.02
9 (77) 162 (74) 0.4
30 0.02
13 0.3
27 0.5
19 0.5
46 0.4
20 0.5
50 0.5
55 0.9
52 0.02
31 0.02
18 0.02
40 b0.001
26 0.05
17 0.3
31 0.02
85 0.01
11 0.1
ercutaneous coronary intervention.
Table 2
Association between beta blocker therapy and depressive symptoms at baseline and at 12 months post PCI.
Beta blockers % Depressive symptoms Mean (SD) depressive symptoms Depression (univariable)
OR [95% CI]
Depression (multivariable)
OR [95% CI]
Baseline BBL+ 15.9 4.32 (3.7) 0.85 [0.55–1.29] 0.82 [0.53–1.26]
BBL− 18.3 4.59 (3.9)
12 months BBL+ 9.7 3.71 (3.2) 0.53 [0.33–0.84] 0.51 [0.31–0.84]
BBL− 16.9 4.62 (3.6)
BBL = Beta Blocker; OR = Odds ratio; and CI = Confidence interval.
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beta blocker dose
There was a clear dose–response relationship between
beta blocker dose and depressive symptoms, with the pattern
being more clear at 12 months post PCI than at baseline
(Fig. 1). A higher dose of beta blocker therapy was associated
with a reduced risk of depressive symptoms, in particular at
12 months, with the risk reduction in depressive symptoms
in relation to a low dose being 36% (OR: 0.64; 95% CI:
0.37–1.10) and 58% (OR: 0.42; 95% CI: 0.24–0.76) in relation
to a high dose (Table 3).
3.5. Lipophilic and hydrophilic beta blocker use
In statistical analyses, we could not take into account the
potential influence of the type of beta blocker (i.e., hydrophilic
versus lipophilic) due to the majority (89%) of patients using a
lipophilic beta blocker. Of the patients using a beta blocker,
89.0% at baseline and 89.3% 12months post PCI in cohorts I
and II used a lipophilic beta blocker against 11.0% and 10.7%
at baseline and 12 months post PCI who used a hydrophilic
beta blocker. Based on percentages, lipophilic beta blocker
users experience depressive symptoms more frequently, com-
pared with hydrophilic beta blocker users (16.0% versus 8.0%
at baseline and 10.3 versus 4.0 at 12-months post-PCI,
respectively).912912 422422 291291
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Fig. 1. Prevalence of depressive symptoms stratified by cohort and dose of beta blocker therapy.3.6. Sensitivity analyses
In order to ensure that the results on merged data were
not driven by a relationship between beta blocker therapy
and depressive symptoms in only one of the cohorts, we
also examined the two cohorts separately. In unadjusted
analysis, there was no significant relationship between beta
blocker therapy and depressive symptoms at baseline in Co-
hort I (OR: 0.71; CI: 0.41–1.24) nor in Cohort II (OR: 0.72;
CI: 0.35–1.34). Similarly, in adjusted analysis there was no
significant association between beta blocker therapy and de-
pressive symptoms at baseline in Cohorts I (OR: 0.61; CI:
0.34–1.10) and II (OR: 0.82; CI: 0.38–1.78).
Furthermore, linear regression was applied to investigate
the association between beta blocker therapy and depressive
symptoms when the dichotomous depression scale was
replaced by the continuous scale of the HADS in the analysis.
At baseline and 12 months post PCI, the results of the unad-
justed (p-value 0.38 and 0.001) and adjusted (p-value 0.50
and 0.002) analysis was in accordance with the prior analysis.
When stratifying beta blocker use by dose (i.e., low versus
high) and no beta blocker therapy as the reference category,
there were no statistically significant differences at baseline
for low beta blocker dose (OR: 0.90; CI: 0.49–1.65) nor high
beta blocker dose and depressive symptoms in Cohorts I
(OR: 0.55; CI: 0.29–1.04) and II (OR: 0.97; CI: 0.42–2.23)
(OR: 0.51; CI: 0.19–1.34). However, at 12 months post PCI
Table 3
Association between beta blocker dose (low versus high) a no beta blocker
use at baseline and at 12 months post PCI.
Depression multivariable
OR (95% CI)
Baselinea
No beta blocker (reference) 1.00
Low dose beta blocker 1.08 [0.67–1.74]
High dose beta blocker 0.64 [0.38–1.07]
12 monthsa
No beta blocker (reference) 1.00
Low dose beta blocker 0.64 [0.37–1.10]
High dose beta blocker 0.42 [0.24–0.76]
Low dose beta blocker=b25% of the maximum recommended therapeutic
dose.
High dose beta blocker=≥25% of the maximum recommended therapeutic
dose.
a Depressive symptoms were assessed with the Hospital Anxiety and
Depression Scale (HADS). OR = Odds ratio; CI = Confidence interval.
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high dose (OR: 0.56; CI: 0.26–1.22) were less likely to have de-
pressive symptoms than patients with no beta blocker therapy,
although the associations were not statistically significant. At
12 months in Cohort II, there was also not a statistically signif-
icant association between a low dose and depressive symp-
toms (OR: 0.41; CI: 0.16–1.06), although this was the case for
a high dose of beta blocker therapy (OR: 0.25; CI: 0.08–0.74),
with this effect being higher than in combined analyses on Co-
horts I and II.
In order to rule out the potentially confounding influence
of other types of cardiac medications and indication for PCI,
we examined their association with depressive symptoms
in Cohorts I and II merged together. None of the other types
of cardiac medications or PCI indication was associated with
depressive symptoms neither at baseline nor at 12 months
follow-up (p-values>0.05; results not shown).
We examinedwhether beta blocker therapywas associated
with anxiety at baseline and at 12 month post PCI in Cohorts I
and II merged together (Table 4). In unadjusted analysis,
there was no significant relationship between beta blocker
therapy and anxiety at baseline (OR: 0.72; CI: 0.40–1.32) nor
at 12 months post PCI (OR: 0.51; CI: 0.25–1.02). In adjusted
analysis there was no significant association between beta
blocker therapy and anxiety at baseline (OR: 0.66; CI:
0.36–1.23) but at 12 months post PCI there was significant as-
sociation (OR: 0.42; CI: 0.20–0.87).
4. Discussion
The objective of the current study was to examine the as-
sociation between beta blocker therapy and depressiveTable 4
Association between beta blocker therapy and anxiety at baseline and at
12 months post PCI.
Anxiety (univariable)
OR (95% CI)
Anxiety (multivariable)
OR (95% CI)
Baselinea 0.72 [0.40–1.32] 0.66 [0.36–1.23]
12 monthsa 0.51 [0.25–1.02] 0.42 [0.20–0.87]
a Anxiety was assessed with the Hospital Anxiety and Depression Scale
(HADS); OR = Odds ratio; CI = Confidence interval.symptoms in patients treated with PCI and the extent to
which there is a dose–response relationship between beta
blocker dose and depressive symptoms. Compared to the
study by van Melle et al. (2006), we focused not only on
post MI patients but also on patients with stable and unstable
angina as indication for PCI.
We found that beta blocker therapy was not associated
with depressive symptoms at baseline, while at 12 months
post PCI patients on beta blocker therapy had a 47% risk re-
duction in depressive symptoms in unadjusted analysis and
a 49% risk reduction in adjusted analysis. We also found a
dose–response relationship, particularly at 12 months post
PCI, with a higher dose of beta blockers being associated
with a more significant risk reduction in depressive symp-
toms. The risk reduction in depressive symptoms for a low
dose was 36% and 58% for a high dose, respectively, com-
pared to no beta blocker therapy.
We can only speculate why beta blocker therapy may
have protective effects against depressive symptoms in pa-
tients after PCI. Previous animal studies with fear as the
main outcome have shown that these memories can change
when recalled (Kindt et al., 2009), and also that behavioral
expression of fear in humans can be erased before memory
reactivation with the beta adrenergic receptor antagonist
propranolol (Kindt et al., 2009). Maybe beta blockers are po-
tent not only with respect to erasing fear but also with re-
spect to reducing depressive symptoms. When looking at
the heart rate variability literature, there might be a link be-
tween depression and reduced heart rate variability (Grippo
and Johnson, 2002). However, beta blocker use, such as met-
oprolol and atenolol, has been shown to increase heart rate
variability in CAD (Niemela et al., 1994). Hypothetically, if
heart rate variability increases with beta blocker therapy,
and if heart rate variability is causally related to depressive
symptoms, our findings support this hypothesis.
An alternative explanation for the conflicting findings
with respect to the association between beta blocker therapy
and depression to date could be the definition of depression
used in previous studies, with some studies having used anti-
depressant prescription as a marker for depression (Avorn
et al., 1986; Thiessen et al., 1990). Because antidepressant
medication is prescribed not only for psychiatric indications
but also for pain management and induction of sleep, this is
not an optimal proxy for depressive symptoms (Gerstman
et al., 1996). Furthermore, fatigue, a common beta blocker
side effect, may have been misinterpreted as depression,
which could lead to an overestimation of depression (Goble,
1992; Patten and Barbui, 2004).
Previous studies have also demonstrated that pindolol has a
significant affinity for the 5-HT1A receptor (Plenge andMellerup,
2003). The inhibition of 5-HT-uptake results in an antidepressant
effect. Therefore, pindolol is comparable to the working mecha-
nismof selective serotonin reuptake inhibitors (SSRIs). Especially
the combination of paroxetine (an SSRI) with pindolol creates a
nearly complete blockade of the 5-HT transporter already after
the first dose (Plenge and Mellerup, 2003). This, in combination
with beta blocker therapy, could be an explanation for the bor-
derline significance of the positive trend toward lower depres-
sive symptoms at 12 months post PCI. Unfortunately, in the
current study we did not have information on the use of anti-
depressant medication.
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pressive symptoms at 12 months in patients on beta blocker
therapy while van Melle et al. (2006) found a trend to less de-
pressive symptoms already at 3 months in post MI patients. In
part, these resultsmay be attributed to type of beta blocker (Ried
et al., 1998), as several studies have suggested that the risk of
central nervous system (CNS) adverse effects is greater for lipo-
philic than for hydrophilic beta blockers (Drayer, 1987; Gengo et
al., 1987; Theodoresen and Brors, 1989) due to lipophilic drugs
more readily crossing the blood–brain barrier than hydrophilic
drugs (Ried et al., 1998). Hence, if the hypothesis is true that
beta blocker use increases the risk of depression, propranolol is
the most likely offender because it is the most lipophilic type
(Steffensmeier et al., 2006). However, for atenolol and nadolol
there is only minimal evidence that they lead to depression
(McNeil et al., 1982). Ko et al. (2002) even found a non signifi-
cant trend toward a higher risk of depressive symptoms in low
to moderate lipid solubility beta blockers compared with beta
blockers that have a high lipid solubility. von Kanel and Begre
(2006) demonstrated that in the meta-analysis of Ko et al.
(2002) the overall prevalence of depressive symptoms in pa-
tients who used and who did not use beta blockers was similar.
They also noticed that neither the lipophilic nor the hydrophilic
beta blocker compounds did have a part in this. In the current
study, we were not able to examine whether the type of beta
blocker (i.e., lipophilic versus hydrophilic) influenced the results,
as the majority of patients (90%) on beta blocker therapy were
prescribed a lipophilic beta blocker.
The results of the current study should be interpreted with
some caution. First, we used two independent cohorts of post
PCI patients, with the sample size ranging between 279 and
406 in the two registries. Furthermore, it is possible that a selec-
tion bias might have occurred, given that some patients did not
return the questionnaire, or were unable to complete the ques-
tionnaire due to insufficient knowledge of the Dutch language.
In addition, patients who died within the first 1 month post
PCI or between 1 month and 12 months post PCI were not
able to complete theHADS,whichmight potentially have biased
the results. Second, we did not have data on psychoactive drug
use or psychological support of the patients before they were
enrolled in the study. Third, in statistical analyses we were not
able to take into account whether the type of beta blocker (i.e.,
hydrophilic versus lipophilic) had an influence on depressive
symptoms, given that the majority of patients on beta blocker
therapy were prescribed a lipophilic beta blocker. Fourth, it is
uncertain whether patients, who had a prescription for a beta
blocker, actually took their medication, or complied with their
dosing regimen.
In conclusion, the results of the current study showed that
patients on beta blocker therapy had a considerable risk reduc-
tion in depressive symptoms 12 months post PCI, with there
being a general dose–response relationship with a higher
dose providing a more pronounced protective effect. Further
studies are warranted to confirm these findings, as to our
knowledge this is the first study to show that beta blocker ther-
apy may have a protective effect against depressive symptoms
in cardiac patients.Role of funding source
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